Previous news here:
Nexstim Initiates Multicenter Clinical Trial on the Therapeutic Effects of Navigated TMS for Stroke Rehabilitation
Company announcement, Helsinki, 7 March 2017 at 11:30 am
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company with a pioneering navigated non-invasive brain stimulation system (NBT® system), announces that it has enrolled the first patients in its supplemental Ph III clinical trial in stroke rehabilitation, known as E-FIT (ELECTRIC FIELD NAVIGATED 1HZ RTMS FOR POST-STROKE MOTOR RECOVERY TRIAL) at the Rancho Los Amigos National Rehabilitation Center, Downey, California, U.S.A.
Commenting on the start of this trial, Jarmo Laine, Vice President Medical Affairs, Nexstim Plc stated: " The E-FIT trial preparations and start-up have gone extremely well. I am very pleased to report the rapid enrolment of clinical sites and our first trial subjects and we look forward to bringing the rehabilitation benefits that our NBT® system could deliver to stroke patients in the US in addition to Europe where we already have CE mark approval."
Martin Jamieson, Chairman and CEO
Martin Jamieson, Chairman and CEO firstname.lastname@example.org
UB Securities Oy (Certified Adviser) +358 (0)9 2538 0246
Citigate Dewe Rogerson +44 (0)207 2821066
Katja Stout email@example.com
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE marked for the treatment of chronic neuropathic pain, major depression and stroke. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com